secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2021-11-17T23:59:59+00:00
Accession:  0001193125-21-331947
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Therapeutics appoints Sonja L. Banks to board of directors
------------------------------------------------------------------

- Sonja Banks elected as Class I director, effective December 8, 2021, with term expiring at 2023 annual meeting.
- Banks is CEO of International Dyslexia Association and former president of Sickle Cell Disease Association of America.
- Her election expands the board to nine members; she is deemed independent under Nasdaq rules.
- Banks will receive standard non-employee director compensation including a one-time option to purchase 30,000 shares.
- Fulcrum focuses on rare genetic diseases; Banks brings ~25 years of patient advocacy and nonprofit leadership experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312521331947/0001193125-21-331947-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312521331947/d189896d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-331947

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer